{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:01:14Z","timestamp":1790744474716,"version":"4.1.0"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Recurrent or second primary head and neck cancer (rsHNC) presents a radiotherapeutic challenge due to limited tolerance of previously irradiated tissues. These patients could benefit from dose painting (DP), which focuses on delivering maximal dose to areas of high tumor burden while respecting dose constraints to organs at risk. In this study, we compare clinical outcomes in one group receiving standard reirradiation with a group receiving 18F-fluorodeoxyglucose (FDG) PET\/CT-guided DP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Our standard reirradiation regimen is hyperfractionated radiotherapy (RT) of 1.5 Gy x 40 (60 Gy total dose). For DP, we defined two FDG-based prescription volumes receiving at least 65 Gy and 70 Gy. Thirteen patients receiving standard RT were compared with 10 DP patients. Toxicity was scored using CTCAE v3.0. Disease-related endpoints were locoregional control (LRC), disease-free survival (DFS) and overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mean composite toxicity score was maximal at the end of RT, with varying patterns across the CTCAE items. No significant difference in toxicity was found between the groups except for dysphagia at 6 months, where the standard RT group had worse scores (p=0.01). No differences were found in LRC and DFS. Two-year OS was 50% in the DP group versus 15% in the standard group (p=0.04), although this may reflect higher comorbidity in the standard group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>DP of rsHNC did not increase toxicity compared with standard reirradiation. No evidence of improved disease control was found. However, DP may benefit selected patients, and future studies should focus on identifying these candidates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:related-object>\n                      <jats:ext-link>https:\/\/clinicaltrials.gov<\/jats:ext-link>\n                      , identifier NCT02921581.\n                    <\/jats:related-object>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1966123","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:50:59Z","timestamp":1790743859000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical outcomes after reirradiation with dose painting of recurrent or second primary head and neck cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Einar","family":"Dale","sequence":"first","affiliation":[{"name":"Department of Oncology, Oslo University Hospital","place":["Oslo, Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten E.","family":"Evensen","sequence":"additional","affiliation":[{"name":"Section of Oncology, Drammen Hospital, Vestre Viken Hospital Trust","place":["Drammen, Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilie D.","family":"Amdal","sequence":"additional","affiliation":[{"name":"Department of Oncology, Oslo University Hospital","place":["Oslo, Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torbj\u00f8rn","family":"Furre","sequence":"additional","affiliation":[{"name":"Department of Medical Physics, Oslo University Hospital","place":["Oslo, Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon M.","family":"Moan","sequence":"additional","affiliation":[{"name":"Department of Oncology, Oslo University Hospital","place":["Oslo, Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liv Cathrine","family":"Heggeb\u00f8","sequence":"additional","affiliation":[{"name":"Department of Oncology, Oslo University Hospital","place":["Oslo, Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayca M.","family":"L\u00f8ndalen","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Innlandet Hospital Trust","place":["Gj\u00f8vik, Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirik","family":"Malinen","sequence":"additional","affiliation":[{"name":"Department of Radiation Biology, Institute for Cancer Research, Oslo University Hospital","place":["Oslo, Norway"]},{"name":"Department of Physics, University of Oslo","place":["Oslo, Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3857\/roj.2013.31.4.206","article-title":"Re-irradiation of unresectable recurrent head and neck cancer: using Helical Tomotherapy as image-guided intensity-modulated radiotherapy","volume":"31","author":"Jeong","year":"2013","journal-title":"Radiat Oncol J"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19941001)74:7<1933::aid-cncr2820740718>3.0.co;2-x","article-title":"Synchronous and metachronous head and neck carcinomas","volume":"74","author":"Schwartz","year":"1994","journal-title":"Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2011.01.004","article-title":"Reirradiation for head-and-neck cancer: delicate balance between effectiveness and toxicity","volume":"81","author":"Hoebers","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/hed.23227","article-title":"Decision making in the management of recurrent head and neck cancer","volume":"36","author":"Ho","year":"2014","journal-title":"Head Neck"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2014.04.018","article-title":"High-dose reirradiation with intensity-modulated radiotherapy for recurrent head-and-neck cancer: disease control, survival and toxicity","volume":"111","author":"Duprez","year":"2014","journal-title":"Radiotherapy Oncol J Eur Soc For Ther Radiol Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/hed.20942","article-title":"Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer","volume":"31","author":"Machtay","year":"2009","journal-title":"Head Neck"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2012.03.001","article-title":"Can \"early\" and \"late\" 18F-FDG PET-CT be used as prognostic factors for the clinical outcome of patients with locally advanced head and neck cancer treated with radio-chemotherapy","volume":"103","author":"Castaldi","year":"2012","journal-title":"Radiotherapy Oncol J Eur Soc For Ther Radiol Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2014.06.001","article-title":"Recurrences after intensity modulated radiotherapy for head and neck squamous cell carcinoma more likely to originate from regions with high baseline [18F]-FDG uptake","volume":"111","author":"Due","year":"2014","journal-title":"Radiotherapy Oncol J Eur Soc For Ther Radiol Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2018.1512753","article-title":"Dose painting for re-irradiation of head and neck cancer","volume":"57","author":"Skjotskift","year":"2018","journal-title":"Acta Oncol (Stockholm Sweden)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-018-1293-3","article-title":"A feasibility study on adaptive (18)F-FDG-PET-guided radiotherapy for recurrent and second primary head and neck cancer in the previously irradiated territory","volume":"194","author":"Schatteman","year":"2018","journal-title":"Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al]"},{"key":"B11","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1186\/s12885-025-13969-5","article-title":"Reirradiation based on diffusion-weighted magnetic resonance imaging-guided dose-painting for locally advanced recurrent nasopharyngeal carcinoma: a phase 2 randomized controlled trial","volume":"25","author":"Tan","year":"2025","journal-title":"BMC Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2023.100654","article-title":"Impact of hyperfractionated re-irradiation on quality of life in patients with recurrent or second primary head and neck cancer, a prospective single institutional study","volume":"42","author":"Amdal","year":"2023","journal-title":"Clin Trans Radiat Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2006.03.003","article-title":"18F]fluoro-deoxy-glucose positron emission tomography ([18F]FDG-PET) voxel intensity-based intensity-modulated radiation therapy (IMRT) for head and neck cancer","volume":"79","author":"Vanderstraeten","year":"2006","journal-title":"Radiotherapy Oncol J Eur Soc For Ther Radiol Oncol"},{"key":"B14","volume-title":"Rstudio: Integrated Development Environment for R","year":"2023"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2006.02.003","article-title":"A phase II study of primary reirradiation in squamous cell carcinoma of head and neck","volume":"78","author":"Langendijk","year":"2006","journal-title":"Radiotherapy Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.meddos.2026.05.004","article-title":"Redefining plan quality in head-and-neck VMAT via RayStation MCO versus standard optimization: A dual analysis of dosimetry and delivery accuracy","author":"Bannan","year":"2026","journal-title":"Med Dosim"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1966123\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:51:02Z","timestamp":1790743862000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1966123\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":16,"alternative-id":["10.3389\/fonc.2026.1966123"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1966123","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"article-number":"1966123"}}